"drug development"

Eli Lilly's acquisition of AtaiBeckley for up to $3.8 billion, marks a pivotal moment for psychedelic medicine.

The real story is that we're approaching the ability to read, interpret and eventually intervene in the human body's operating system.

In this week’s edition of InnovationRx, we look at the boom in autoimmune disease therapies, OpenAI’s healthcare push, Vertex’s $10 billion...

In this week’s edition of InnovationRx, we look at AbbVie’s new megadeal, an agentic AI startup saving Medicare $2 million a week, how new s...

The real issue is whether we can build a learning loop in which human expertise improves digital systems, and digital systems strengthen hum...

In this week’s edition of InnovationRx, we look at the AI drug discovery startup Lilly and Pfizer are betting on, the greatest living immigr...

The Code as Witness written by Steven C. Quay is part scientific investigation, part policy strategy, and part warning about the future of b...

Kordata launched from stealth, spun out of BIOS to target CNS trials with neurotech and enterprise